Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin Combined With Methylprednisolone for Hyperthyroidism Exophthalmos
NCT05532072Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sirolimus in Graves' ophthalmopathy (TED) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Response Rate (CAS, Eye Cleft Width, Eye Movement) at 24 weeks and Treatment-Related Adverse Events at 24 weeks. Status: unknown.
02
Drugs
sirolimus
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT05532072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532072.